Lead Tx Program: NTX-1024
The company’s developing ocular program (NTX-1024) is a formulation of a sterile eye drop containing a proprietary compound and formulation for chronic treatment of atopic keratoconjunctivitis (AKC), perennial allergic conjunctivitis (PAC), and vernal conjunctivitis (VKC), with a focus on chronic eosinophilic inflammation [Eosinophilic Conjunctivitis, or EC].
NTX-1024 has the potential as a novel effective, non-systemic first line therapy for EC. Current standard of care for EC involves a challenging, multistep process and Primary Care Physicians lack clear practice guidelines for both diagnosis and treatment. As a result, only 10% of EC patients seek treatment, leading to destructive, long term visual consequences. This delay in diagnosis and treatment can lead to sight threatening corneal damage.
NTX-1024 has the potential to offer patients a non-invasive and more comprehensive alternative to assess and treat EC, improving quality of life in the face of symptoms such as itching, burning, tearing, and visual disturbances, with the long-term potential for a loss of sight.
Current treatments for chronic allergy-based conjunctivitis include oral and topical antihistamines and corticosteroids. Due to common use of topical and oral corticosteroids, glaucoma is a potential complication of treatment.
NTX-1024 targets inflammatory proteins in the ocular tear film that are associated with allergic diseases. Our proprietary glycosaminoglycan resides on the ocular tear film only, where it targets inflammatory proteins to relieve symptoms.